



**MONTHLY DOSE**  
**FEBRUARY 2021**

## News for the Month

### Company

- Dr. Reddy's Laboratories announces the launch of Vigabatrin Tablets, in the US market
- India's demand for Covid-19 drug remdesivir to fall, says Cipla
- Covid-19: Bharat Biotech, Ocugen ink deal for Covaxin supply to US
- Zydus announces completion of Phase-I trials of ZY19489- A single dose cure for Malaria in collaboration with MMV
- Strides to demerge and list its Biotech Business Under Stelis Biopharma
- Pfizer withdraws vaccine plea as panel seeks India trial data
- Biocon Biologics to provide cancer biosimilars to 30 countries in Africa, Asia
- Natco Pharma receives approval for Chlorantraniliprole (CTPR)- 1<sup>st</sup> key product of Crop Health Sciences Division
- Zydus completes large scale enrolment for two Phase III trials of Desidustat
- Sun Pharma recalls 36,275 cartons of testosterone injection in the US for labelling error
- AstraZeneca vaccine less effective against S.African strain: study
- Alembic Pharma gets five observations from USFDA for Gujarat facility
- Novel blood cancer drug developed by Alembic Pharma's associate Rhizen gets US approval
- Glenmark launches SUTIB (Sunitinib)- priced 96% lower than the innovator brand
- Biocon Biologics joins hands with IDF in its mission to promote diabetes care, prevention and effective management worldwide
- Lupin launches Posaconazole DR tablets
- DRL announces the launch of Capecitabine tablets in the US market
- Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride tablets in the US market
- Dr. Reddy's initiates process for Emergency Use Authorization of Sputnik V
- Unichem Laboratories gets USFDA nod for plaque psoriasis treatment drug
- Dr. Reddy's Laboratories announces the launch of Lansoprazole DR orally disintegrating tablets in the US market
- Glenmark's Ryaltris- innovative single nasal spray, ready to market in Russia
- Aurobindo Pharma acquire 26% stake each in 2 solar power firms
- Sun Pharma to introduce complete range of Brivaracetam at an affordable price for epilepsy treatment in India
- Zydus Cadila's US subsidiary acquires experimental drug from Cyprium for treating Menkes disease
- Strides Pharma Science arm gets American drug regulator's nod for pain relieving drug
- Sun Pharma launches website for its Long-Term Care (LTC) Portfolio in the US
- Cipla in talks to bring Covid antidotes to India
- NATCO launches Brivaracetam tablets, in India, for treatment of epilepsy

### Industry

- Higher Budget allocation for healthcare a welcome move for the sector, says Industry
- Pharma exports up 12.43% during April-December 2020-21
- Cabinet approves Rs15,000cr PLI scheme for pharma sector
- Govt continuously working to improve ease of doing biz in pharma sector: Sadananda Gowda

### Global

- Sanofi and GSK begin new study of their Covid-19 vaccine
- Amgen looks to expand access to Otezla in the US

Source: Media Reports and Company Press Releases

**Final ANDA Approvals:**

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
Glenmark	Topiramate ER Capsules	25/50/100/150/200 mg	Used to treat seizures	Qudexy XR Capsules (Upsher-Smith Laboratories, LLC.)	USD120.8mn (Annual sales)
Strides	Prednisone Tablets	10/20mg	Used in treatment of different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders	Deltasone Tablets (Pharmacia and Upjohn Co.)	USD60mn
Alembic	Treprostinil Injection	20mg/20ml (1mg/ml), 50mg/20ml (2.5mg/ml), 100mg/20ml (5mg/ml), and 200mg/20ml (10mg/ml), Multiple-Dose Vials	Indicated for the treatment of pulmonary arterial hypertension	Remodulin Injection (United Therapeutics Corp.)	USD17mn
Lupin	Droxidopa Capsules	100/200/300mg	Indicated for the treatment of orthostatic dizziness, lightheadedness	Nothera (Lundbeck NA Ltd.)	USD352mn (Annual sales)
Aurobindo	Droxidopa Capsules	100/200/300mg	Indicated for the treatment of orthostatic dizziness, lightheadedness	Nothera (Lundbeck NA Ltd.)	USD352mn
Cadila	Droxidopa Capsules	100/200/300mg	Indicated for the treatment of orthostatic dizziness, lightheadedness	Nothera (Lundbeck NA Ltd.)	USD352mn
Cadila	Nortriptyline Hydrochloride Capsules	10/25/50/75mg	Used to treat mental/mood problems such as depression	Pamelor Capsules	-
Strides	Ibuprofen Oral Suspension	100mg/5mL (OTC)	It is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain from various conditions such as headache, dental pain, muscle aches	Motrin (Johnson & Johnson Consumer Inc. )	USD133mn
Unichem	Apremilast Tablets	10/20/30mg	Indicated for the treatment of adult patients with moderate to severe plaque psoriasis	Otezla (Amgen)	USD2.7bn (Annual sales)

Source: Media Reports and Company Press Releases



BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
Aarti Drugs Ltd	631	-9.3%	-78.5%	-15.5%
Abbott India Ltd	14397	-0.9%	-15.0%	-11.4%
Ajanta Pharma Ltd	1748	0.8%	8.5%	23.8%
Alembic Ltd	102	8.2%	18.9%	109.1%
Alembic Pharmaceuticals Ltd	919	-3.5%	-7.2%	41.9%
Alkem Laboratories Ltd	2719	-11.1%	-3.6%	3.2%
Apollo Hospitals Enterprise Ltd	3061	17.7%	85.1%	73.0%
AstraZeneca Pharma India	3438	-8.4%	-2.4%	29.3%
Aurobindo Pharma Ltd	855	-10.9%	-1.5%	67.6%
Biocon Ltd	390	3.3%	-0.6%	30.6%
Bliss GVS Pharma Ltd	175	-8.1%	10.5%	36.2%
Cadila Healthcare Ltd	435	-5.9%	11.8%	65.3%
Caplin Point Laboratories Ltd	464	-0.5%	-13.9%	44.7%
Cipla Ltd	787	-6.6%	5.2%	86.2%
Divi's Laboratories Ltd	3368	-3.3%	5.3%	57.2%
Dr. Reddy's Laboratories Ltd	4425	-9.9%	-0.3%	43.9%
Dr. Lal PathLabs Ltd	2302	-2.0%	24.4%	39.8%
Eris Lifesciences Ltd	587	-4.0%	9.5%	42.3%
FDC Ltd	278	-7.6%	-15.1%	12.2%
Fortis Healthcare Ltd	158	-3.5%	16.6%	1.2%
GSK Pharmaceuticals Ltd	1461	-0.6%	-8.0%	7.9%
Glenmark Pharmaceuticals Ltd	467	-3.8%	-4.7%	57.8%
Granules India Ltd	323	-9.0%	4.4%	86.4%
Gufic Biosciences Ltd	120	3.1%	33.1%	75.6%
HealthCare Global Enterprises Ltd	170	5.9%	31.5%	51.7%
Hester Biosciences Ltd	1789	8.4%	14.8%	17.8%
Hikal Ltd	159	-7.0%	-6.9%	18.9%
Indoco Remedies Ltd	292	-8.9%	16.8%	11.0%
Indraprastha Medical Corp. Ltd	53	-1.4%	-0.7%	28.7%
IOL Chemicals and Pharma Ltd	554	-22.0%	-35.3%	85.4%
IPCA Laboratories Ltd	1849	-4.9%	-7.9%	34.6%
J.B. Chemicals & Pharma Ltd	1117	9.9%	41.5%	99.5%
Jubilant Life Sciences Ltd	768	-17.1%	-9.7%	50.9%
Kopran Ltd	120	6.5%	59.0%	311.3%


Source: BSE website;  
All prices are as on 26th February 2021

BSE Health Care Index Price Performance				
Companies	Price	Change		
		1 M	6 M	12 M
Laurus Labs Ltd	350	-4.3%	52.3%	317.7%
Lincoln Pharmaceuticals Ltd	226	0.6%	-8.1%	29.9%
Lupin Ltd	1019	-5.2%	4.1%	52.2%
Mangalam Drugs and Organics Ltd	124	-0.8%	-20.3%	323.8%
Marksans Pharma Ltd	55	1.9%	7.8%	196.3%
Medicamen Biotech Ltd	614	34.1%	48.2%	100.1%
Merck Ltd	6697	-6.7%	33.2%	61.3%
Morepen Laboratories Ltd	29	3.2%	8.0%	118.3%
Narayana Hrudayalaya Ltd	431	-5.2%	27.3%	27.1%
Natco Pharma Ltd	813	-8.2%	-1.4%	30.3%
Nectar Lifesciences Ltd	20	0.5%	-17.6%	69.8%
Neuland Laboratories Ltd	2029	46.6%	100.8%	377.4%
Novartis India Ltd	623	-4.4%	-3.2%	4.8%
Opto Circuits India Ltd	4	-14.3%	-41.6%	63.5%
Panacea Biotec Ltd	198	0.7%	2.6%	80.2%
Pfizer Ltd (India)	4551	-3.3%	-6.3%	8.5%
Piramal Enterprises Ltd	1823	28.7%	27.5%	27.9%
Poly Medicure Ltd	706	37.0%	64.5%	125.2%
RPG Life Sciences Ltd	415	-0.4%	8.6%	57.7%
Sanofi India Ltd	8269	3.5%	-4.7%	16.2%
Shalby Ltd	107	-0.6%	20.9%	18.7%
Shilpa Medicare Ltd	369	-12.5%	-36.1%	-24.6%
SMS Pharmaceuticals Ltd	131	17.4%	41.7%	251.9%
Strides Shasun Ltd	834	2.2%	36.7%	70.0%
SPARC Ltd	164	-11.1%	-9.4%	6.1%
Sun Pharmaceutical Industries Ltd	595	4.5%	13.4%	58.9%
Suven Life Sciences Ltd	85	16.2%	58.2%	36.5%
Syngene International Ltd	559	-5.2%	13.7%	81.8%
Thyrocare Technologies Ltd	908	-0.1%	19.5%	52.1%
Torrent Pharmaceuticals Ltd	2430	-8.2%	-11.8%	8.0%
Unichem Laboratories Ltd	335	15.9%	25.6%	146.9%
Vimta Labs Ltd	165	1.7%	47.4%	64.8%
Vivimed Labs Ltd	15	-4.0%	-24.0%	51.3%
Wockhardt Ltd	501	3.0%	54.6%	48.6%

Source: BSE website;  
All prices are as on 26th February 2021

NIFTY PHARMA COMPANIES					
Company	Price (Rs)	Mcap (Rsmn)	Change		
			1 M	6 M	12 M
Aurobindo Pharma Ltd.	855	500919	-10.90%	-1.5%	67.6%
Biocon Ltd.	390	468000	3.3%	-0.6%	30.6%
Cadila Healthcare Ltd.	435	445072	-5.9%	11.8%	65.3%
Cipla Ltd.	787	634225	-6.6%	5.2%	86.2%
Divi's Laboratories Ltd.	3368	894165	-3.3%	5.3%	57.2%
Dr. Reddy's Laboratories Ltd.	4425	735677	-9.9%	-0.3%	43.9%
Glenmark Pharmaceuticals Ltd.	467	131773	-3.8%	-4.7%	57.8%
Lupin Ltd.	1019	461625	-5.2%	4.09%	52.2%
Piramal Enterprises Ltd.	1829	412397	28.7%	27.5%	27.9%
Sun Pharmaceutical Industries Ltd.	595	1428324	4.5%	13.4%	58.9%

Source: NSE website, Company Research; All prices are as on 26th February 2021



Source: NSE website



## DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products. PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

**Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-**

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research Analyst has served as officer, director or employee of the subject company: NO

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

### Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:  
Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai-400053;  
[www.progressiveshares.com](http://www.progressiveshares.com)  
Contact No.:022-40777500.

Compliance Officer:  
Mr. Shyam Agrawal,  
Email Id: [compliance@progressiveshares.com](mailto:compliance@progressiveshares.com),  
Contact No.:022-40777500.